What is Zacks Research’s Forecast for Moderna Q2 Earnings?

Moderna, Inc. (NASDAQ:MRNA) – Analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of Moderna in a note issued to investors on Wednesday, May 21st. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings per share of ($3.26) for the quarter, down from their previous forecast of ($3.10). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Zacks Research also issued estimates for Moderna’s Q3 2025 earnings at ($2.09) EPS, Q4 2025 earnings at ($2.67) EPS, Q1 2026 earnings at ($2.26) EPS, Q2 2026 earnings at ($2.84) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($8.18) EPS, Q1 2027 earnings at ($1.88) EPS and FY2027 earnings at ($4.43) EPS.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business’s quarterly revenue was down 35.3% on a year-over-year basis. During the same period last year, the business earned ($3.07) EPS.

Several other brokerages have also recently weighed in on MRNA. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. Finally, UBS Group cut their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $53.58.

Moderna Stock Down 1.7%

Shares of MRNA opened at $26.26 on Monday. The stock has a market capitalization of $10.16 billion, a P/E ratio of -2.83 and a beta of 1.99. Moderna has a twelve month low of $23.15 and a twelve month high of $164.73. The company has a 50 day moving average of $27.08 and a 200-day moving average of $34.39.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MRNA. S Bank Fund Management Ltd bought a new position in Moderna during the 1st quarter worth $25,000. SVB Wealth LLC bought a new position in Moderna during the 1st quarter worth $28,000. Costello Asset Management INC bought a new position in Moderna during the 1st quarter worth $30,000. Sentry Investment Management LLC bought a new position in Moderna during the 1st quarter worth $31,000. Finally, Deseret Mutual Benefit Administrators increased its position in Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after buying an additional 392 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.